TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5
Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not
amenable to surgery or local ablative therapy.